Growth Metrics

Palisade Bio (PALI) Non-cash Items (2015 - 2026)

Palisade Bio (PALI) reported Non-cash Items of $100000.0 for Q1 2026, down 66.67% year-over-year from $300000.0 in Q1 2025, and little changed on a QoQ basis from $100000.0 in Q4 2025.

Palisade Bio (PALI) has 12 years of Non-cash Items data on file, last reported at $100000.0 in Q1 2026.

  • Quarterly Non-cash Items fell 66.67% year-over-year to $100000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $100000.0 (down 66.67% YoY) and the FY2025 annual result came in at $100000.0, down 50.0% from the prior year.
  • Non-cash Items was little changed at $100000.0 in Q1 2026 per PALI's latest filing, from $100000.0 in the prior quarter.
  • Across five years, Non-cash Items topped out at $1.1 million in Q3 2022 and bottomed at $43000.0 in Q1 2022.
  • The 5-year median for Non-cash Items is $250000.0 (2024), against an average of $336225.4.
  • Peak annual rise in Non-cash Items reached 1062.79% in 2023, while the deepest fall reached 94.17% in 2023.
  • Tracing PALI's Non-cash Items over 5 years: stood at $1.1 million in 2022, then plunged by 94.17% to $64155.0 in 2023, then jumped by 211.74% to $200000.0 in 2024, then tumbled by 50.0% to $100000.0 in 2025, then changed by 0.0% to $100000.0 in 2026.
  • Per Business Quant, the three latest PALI Non-cash Items figures stand at $100000.0 (Q1 2026), $100000.0 (Q4 2025), and $200000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Palisade Bio 439.25 Mn 309.68 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 100,000.00
Mar 31, 2026 100,000.00
Dec 31, 2025 100,000.00
Dec 31, 2025 100,000.00
Sep 30, 2025 200,000.00
Sep 30, 2025 200,000.00
Jun 30, 2025 200,000.00
Jun 30, 2025 200,000.00
Mar 31, 2025 300,000.00
Mar 31, 2025 300,000.00
Dec 31, 2024 200,000.00
Dec 31, 2024 200,000.00
Sep 30, 2024 300,000.00
Sep 30, 2024 300,000.00
Jun 30, 2024 400,000.00
Jun 30, 2024 400,000.00
Mar 31, 2024 400,000.00
Mar 31, 2024 400,000.00
Sep 30, 2023 64,155.00
Sep 30, 2023 64,155.00
Jun 30, 2023 800,000.00
Jun 30, 2023 800,000.00
Mar 31, 2023 500,000.00
Mar 31, 2023 500,000.00
Sep 30, 2022 1.10 Mn
Sep 30, 2022 1.10 Mn
Mar 31, 2022 43,000.00
Mar 31, 2022 43,000.00
Jun 30, 2021 759,743.00
Jun 30, 2021 759,743.00
Mar 31, 2021 153,024.00
Mar 31, 2021 153,024.00
Dec 31, 2020 1.54 Mn
Dec 31, 2020 1.54 Mn
Sep 30, 2020 587,000.00
Sep 30, 2020 587,000.00
Jun 30, 2020 64,937.00
Jun 30, 2020 64,937.00
Mar 31, 2020 219,202.00
Mar 31, 2020 219,202.00
Dec 31, 2019 207,813.00
Dec 31, 2019 207,813.00
Sep 30, 2019 384,000.00
Sep 30, 2019 384,000.00
Jun 30, 2019 98,621.00
Jun 30, 2019 98,621.00
Mar 31, 2019 1.80 Mn
Mar 31, 2019 1.80 Mn
Dec 31, 2018 179,000.00
Dec 31, 2018 179,000.00
Sep 30, 2018 363,000.00
Sep 30, 2018 363,000.00
Jun 30, 2018 491,000.00
Jun 30, 2018 491,000.00
Mar 31, 2018 94,000.00
Mar 31, 2018 94,000.00
Dec 31, 2017 108,000.00
Dec 31, 2017 108,000.00
Sep 30, 2017 1.24 Mn
Sep 30, 2017 1.24 Mn
Jun 30, 2017 1.44 Mn
Jun 30, 2017 1.44 Mn
Mar 31, 2017 1.73 Mn
Mar 31, 2017 1.73 Mn
Dec 31, 2016 2.25 Mn
Dec 31, 2016 2.25 Mn
Sep 30, 2016 16.85 Mn
Sep 30, 2016 16.85 Mn
Jun 30, 2016 3.15 Mn
Jun 30, 2016 3.15 Mn
Dec 31, 2015 550,000.00
Dec 31, 2015 550,000.00